ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Study Identifier:
D928DC00001
ClinicalTrials.gov Identifier:
NCT05746559
EudraCT Identifier:
2022-501802-36
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
1-855-752-2356 or [email protected]
Recruiting

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Placebo
  • Drug: Ravulizumab
Date
Apr 2023 - May 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 90 Years
Requirements Information
Sex
Female & Male
Age
18 - 90 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Placebo
  • Drug: Ravulizumab
Date
Apr 2023 - May 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 90 Years years
Requirements Information

Protocol Summary

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.

Trial Locations

Location
Status
Location
Research Site
Tucson, Arizona, United States, 85719
Status
Not yet recruiting
Location
Research Site
Orange, California, United States, 92868
Status
Recruiting
Location
Research Site
San Francisco, California, United States, 94121
Status
Recruiting
Location
Research Site
San Francisco, California, United States, 94143
Status
Recruiting
Location
Research Site
Stanford, California, United States, 94305
Status
Recruiting
Location
Research Site
Aurora, Colorado, United States, 80045
Status
Recruiting